PET parameters of salivary and lacrimal glands and systemic regions in pSS patients with and without lymphoma
| . | Patients with pSS associated lymphoma (N = 26) . | Patients without lymphoma (N = 44) . | P-value . |
|---|---|---|---|
| Parotid glands | |||
| Visual uptake ≥2 | 22 (88.0) | 20 (45.5) | <0.001 |
| SUVmax | 4.86 (3.01–8.71) | 2.29 (1.69–2.86) | <0.001 |
| Diameter (transversal), cm | 3.31 (2.31–4.02) | 2.62 (2.16–3.22) | 0.049 |
| Diameter (frontal), cm | 4.49 (3.91–5.25) | 3.32 (2.86–4.19) | <0.001 |
| Submandibular glands | |||
| Visual uptake ≥2 | 16 (66.7) | 15 (34.9) | 0.012 |
| SUVmax | 3.32 (2.60–6.52) | 2.42 (1.66–2.83) | <0.001 |
| Diameter (transversal), cm | 1.60 (1.40–2.33) | 1.70 (1.23–1.86) | 0.471 |
| Lacrimal glands | |||
| Visual uptake ≥1 | 7 (28.0) | 3 (6.8) | 0.029 |
| SUVmax | 1.84 (1.43–2.63) | 1.63 (1.37–2.00) | 0.162 |
| Lymphoid organs | |||
| Lymph nodes | |||
| Positivity in: | |||
| Any region | 21 (80.8) | 31 (70.5) | 0.340 |
| Cervical region | 13 (52.0) | 16 (36.4) | 0.206 |
| Axillary region | 13 (50.0) | 19 (43.2) | 0.580 |
| Mediastinal region | 10 (38.5) | 21 (47.7) | 0.451 |
| Inguinal region | 9 (34.6) | 15 (34.9) | 0.982 |
| Bone marrow | |||
| SUVmean | 2.04 (1.86–2.51) | 2.00 (1.53–2.43) | 0.419 |
| Spleen | |||
| SUVmean | 2.33 (2.04–2.57) | 2.15 (1.80–2.45) | 0.201 |
| Diameter | 9.51 (7.80–11.85) | 8.72 (7.41–10.04) | 0.315 |
| Tonsils | |||
| SUVmean | 4.18 (3.35–5.04) | 3.19 (2.79–4.49) | 0.022 |
| Other organs | |||
| Visual positivity | |||
| Arthritis | 0 (0) | 4 (9.1) | 0.289 |
| Myositis | 1 (3.8) | 1 (2.3) | 1.000 |
| Enthesitis | 9 (34.6) | 13 (29.5) | 0.659 |
| PMR | 0 (0) | 3 (6.8) | 0.289 |
| Vasculitis | 0 (0) | 0 (0) | NA |
| Nephritis | 0 (0) | 0 (0) | NA |
| Liver | |||
| SUVmean | 2.55 (2.17–2.76) | 2.28 (1.81–2.47) | 0.024 |
| Diameter | 17.1 (15.01–17.81) | 16.88 (15.05–19.09) | 0.644 |
| Pancreas | |||
| Visual pancreatitis | 1 (3.8) | 0 (0) | 0.371 |
| SUVmean | 1.85 (1.56–2.08) | 1.62 (1.29–1.93) | 0.021 |
| Thyroid gland | |||
| Visual thyroiditis | 0 (0) | 1 (2.3) | 1.000 |
| Visual multinodular struma | 1 (4.0) | 5 (11.4) | 0.406 |
| SUVmean | 1.60 (1.33–1.99) | 1.54 (1.25–2.00) | 0.837 |
| Lungs | |||
| Visual inflammatory | 5 (19.2) | 6 (13.6) | 0.534 |
| Visual interstitial | 1 (3.8) | 4 (9.1) | 0.644 |
| Visual lung nodule | 8 (30.8) | 3 (6.8) | 0.015 |
| SUVmean (normal lung parenchyma) | 0.54 (0.47–0.67) | 0.56 (0.41–0.68) | 0.627 |
| . | Patients with pSS associated lymphoma (N = 26) . | Patients without lymphoma (N = 44) . | P-value . |
|---|---|---|---|
| Parotid glands | |||
| Visual uptake ≥2 | 22 (88.0) | 20 (45.5) | <0.001 |
| SUVmax | 4.86 (3.01–8.71) | 2.29 (1.69–2.86) | <0.001 |
| Diameter (transversal), cm | 3.31 (2.31–4.02) | 2.62 (2.16–3.22) | 0.049 |
| Diameter (frontal), cm | 4.49 (3.91–5.25) | 3.32 (2.86–4.19) | <0.001 |
| Submandibular glands | |||
| Visual uptake ≥2 | 16 (66.7) | 15 (34.9) | 0.012 |
| SUVmax | 3.32 (2.60–6.52) | 2.42 (1.66–2.83) | <0.001 |
| Diameter (transversal), cm | 1.60 (1.40–2.33) | 1.70 (1.23–1.86) | 0.471 |
| Lacrimal glands | |||
| Visual uptake ≥1 | 7 (28.0) | 3 (6.8) | 0.029 |
| SUVmax | 1.84 (1.43–2.63) | 1.63 (1.37–2.00) | 0.162 |
| Lymphoid organs | |||
| Lymph nodes | |||
| Positivity in: | |||
| Any region | 21 (80.8) | 31 (70.5) | 0.340 |
| Cervical region | 13 (52.0) | 16 (36.4) | 0.206 |
| Axillary region | 13 (50.0) | 19 (43.2) | 0.580 |
| Mediastinal region | 10 (38.5) | 21 (47.7) | 0.451 |
| Inguinal region | 9 (34.6) | 15 (34.9) | 0.982 |
| Bone marrow | |||
| SUVmean | 2.04 (1.86–2.51) | 2.00 (1.53–2.43) | 0.419 |
| Spleen | |||
| SUVmean | 2.33 (2.04–2.57) | 2.15 (1.80–2.45) | 0.201 |
| Diameter | 9.51 (7.80–11.85) | 8.72 (7.41–10.04) | 0.315 |
| Tonsils | |||
| SUVmean | 4.18 (3.35–5.04) | 3.19 (2.79–4.49) | 0.022 |
| Other organs | |||
| Visual positivity | |||
| Arthritis | 0 (0) | 4 (9.1) | 0.289 |
| Myositis | 1 (3.8) | 1 (2.3) | 1.000 |
| Enthesitis | 9 (34.6) | 13 (29.5) | 0.659 |
| PMR | 0 (0) | 3 (6.8) | 0.289 |
| Vasculitis | 0 (0) | 0 (0) | NA |
| Nephritis | 0 (0) | 0 (0) | NA |
| Liver | |||
| SUVmean | 2.55 (2.17–2.76) | 2.28 (1.81–2.47) | 0.024 |
| Diameter | 17.1 (15.01–17.81) | 16.88 (15.05–19.09) | 0.644 |
| Pancreas | |||
| Visual pancreatitis | 1 (3.8) | 0 (0) | 0.371 |
| SUVmean | 1.85 (1.56–2.08) | 1.62 (1.29–1.93) | 0.021 |
| Thyroid gland | |||
| Visual thyroiditis | 0 (0) | 1 (2.3) | 1.000 |
| Visual multinodular struma | 1 (4.0) | 5 (11.4) | 0.406 |
| SUVmean | 1.60 (1.33–1.99) | 1.54 (1.25–2.00) | 0.837 |
| Lungs | |||
| Visual inflammatory | 5 (19.2) | 6 (13.6) | 0.534 |
| Visual interstitial | 1 (3.8) | 4 (9.1) | 0.644 |
| Visual lung nodule | 8 (30.8) | 3 (6.8) | 0.015 |
| SUVmean (normal lung parenchyma) | 0.54 (0.47–0.67) | 0.56 (0.41–0.68) | 0.627 |
Data are presented as number (%) or median (interquartile range). Bold text highlights significant values. pSS; primary SS: SUVmax/SUVmean: maximum/mean standardized uptake value.
PET parameters of salivary and lacrimal glands and systemic regions in pSS patients with and without lymphoma
| . | Patients with pSS associated lymphoma (N = 26) . | Patients without lymphoma (N = 44) . | P-value . |
|---|---|---|---|
| Parotid glands | |||
| Visual uptake ≥2 | 22 (88.0) | 20 (45.5) | <0.001 |
| SUVmax | 4.86 (3.01–8.71) | 2.29 (1.69–2.86) | <0.001 |
| Diameter (transversal), cm | 3.31 (2.31–4.02) | 2.62 (2.16–3.22) | 0.049 |
| Diameter (frontal), cm | 4.49 (3.91–5.25) | 3.32 (2.86–4.19) | <0.001 |
| Submandibular glands | |||
| Visual uptake ≥2 | 16 (66.7) | 15 (34.9) | 0.012 |
| SUVmax | 3.32 (2.60–6.52) | 2.42 (1.66–2.83) | <0.001 |
| Diameter (transversal), cm | 1.60 (1.40–2.33) | 1.70 (1.23–1.86) | 0.471 |
| Lacrimal glands | |||
| Visual uptake ≥1 | 7 (28.0) | 3 (6.8) | 0.029 |
| SUVmax | 1.84 (1.43–2.63) | 1.63 (1.37–2.00) | 0.162 |
| Lymphoid organs | |||
| Lymph nodes | |||
| Positivity in: | |||
| Any region | 21 (80.8) | 31 (70.5) | 0.340 |
| Cervical region | 13 (52.0) | 16 (36.4) | 0.206 |
| Axillary region | 13 (50.0) | 19 (43.2) | 0.580 |
| Mediastinal region | 10 (38.5) | 21 (47.7) | 0.451 |
| Inguinal region | 9 (34.6) | 15 (34.9) | 0.982 |
| Bone marrow | |||
| SUVmean | 2.04 (1.86–2.51) | 2.00 (1.53–2.43) | 0.419 |
| Spleen | |||
| SUVmean | 2.33 (2.04–2.57) | 2.15 (1.80–2.45) | 0.201 |
| Diameter | 9.51 (7.80–11.85) | 8.72 (7.41–10.04) | 0.315 |
| Tonsils | |||
| SUVmean | 4.18 (3.35–5.04) | 3.19 (2.79–4.49) | 0.022 |
| Other organs | |||
| Visual positivity | |||
| Arthritis | 0 (0) | 4 (9.1) | 0.289 |
| Myositis | 1 (3.8) | 1 (2.3) | 1.000 |
| Enthesitis | 9 (34.6) | 13 (29.5) | 0.659 |
| PMR | 0 (0) | 3 (6.8) | 0.289 |
| Vasculitis | 0 (0) | 0 (0) | NA |
| Nephritis | 0 (0) | 0 (0) | NA |
| Liver | |||
| SUVmean | 2.55 (2.17–2.76) | 2.28 (1.81–2.47) | 0.024 |
| Diameter | 17.1 (15.01–17.81) | 16.88 (15.05–19.09) | 0.644 |
| Pancreas | |||
| Visual pancreatitis | 1 (3.8) | 0 (0) | 0.371 |
| SUVmean | 1.85 (1.56–2.08) | 1.62 (1.29–1.93) | 0.021 |
| Thyroid gland | |||
| Visual thyroiditis | 0 (0) | 1 (2.3) | 1.000 |
| Visual multinodular struma | 1 (4.0) | 5 (11.4) | 0.406 |
| SUVmean | 1.60 (1.33–1.99) | 1.54 (1.25–2.00) | 0.837 |
| Lungs | |||
| Visual inflammatory | 5 (19.2) | 6 (13.6) | 0.534 |
| Visual interstitial | 1 (3.8) | 4 (9.1) | 0.644 |
| Visual lung nodule | 8 (30.8) | 3 (6.8) | 0.015 |
| SUVmean (normal lung parenchyma) | 0.54 (0.47–0.67) | 0.56 (0.41–0.68) | 0.627 |
| . | Patients with pSS associated lymphoma (N = 26) . | Patients without lymphoma (N = 44) . | P-value . |
|---|---|---|---|
| Parotid glands | |||
| Visual uptake ≥2 | 22 (88.0) | 20 (45.5) | <0.001 |
| SUVmax | 4.86 (3.01–8.71) | 2.29 (1.69–2.86) | <0.001 |
| Diameter (transversal), cm | 3.31 (2.31–4.02) | 2.62 (2.16–3.22) | 0.049 |
| Diameter (frontal), cm | 4.49 (3.91–5.25) | 3.32 (2.86–4.19) | <0.001 |
| Submandibular glands | |||
| Visual uptake ≥2 | 16 (66.7) | 15 (34.9) | 0.012 |
| SUVmax | 3.32 (2.60–6.52) | 2.42 (1.66–2.83) | <0.001 |
| Diameter (transversal), cm | 1.60 (1.40–2.33) | 1.70 (1.23–1.86) | 0.471 |
| Lacrimal glands | |||
| Visual uptake ≥1 | 7 (28.0) | 3 (6.8) | 0.029 |
| SUVmax | 1.84 (1.43–2.63) | 1.63 (1.37–2.00) | 0.162 |
| Lymphoid organs | |||
| Lymph nodes | |||
| Positivity in: | |||
| Any region | 21 (80.8) | 31 (70.5) | 0.340 |
| Cervical region | 13 (52.0) | 16 (36.4) | 0.206 |
| Axillary region | 13 (50.0) | 19 (43.2) | 0.580 |
| Mediastinal region | 10 (38.5) | 21 (47.7) | 0.451 |
| Inguinal region | 9 (34.6) | 15 (34.9) | 0.982 |
| Bone marrow | |||
| SUVmean | 2.04 (1.86–2.51) | 2.00 (1.53–2.43) | 0.419 |
| Spleen | |||
| SUVmean | 2.33 (2.04–2.57) | 2.15 (1.80–2.45) | 0.201 |
| Diameter | 9.51 (7.80–11.85) | 8.72 (7.41–10.04) | 0.315 |
| Tonsils | |||
| SUVmean | 4.18 (3.35–5.04) | 3.19 (2.79–4.49) | 0.022 |
| Other organs | |||
| Visual positivity | |||
| Arthritis | 0 (0) | 4 (9.1) | 0.289 |
| Myositis | 1 (3.8) | 1 (2.3) | 1.000 |
| Enthesitis | 9 (34.6) | 13 (29.5) | 0.659 |
| PMR | 0 (0) | 3 (6.8) | 0.289 |
| Vasculitis | 0 (0) | 0 (0) | NA |
| Nephritis | 0 (0) | 0 (0) | NA |
| Liver | |||
| SUVmean | 2.55 (2.17–2.76) | 2.28 (1.81–2.47) | 0.024 |
| Diameter | 17.1 (15.01–17.81) | 16.88 (15.05–19.09) | 0.644 |
| Pancreas | |||
| Visual pancreatitis | 1 (3.8) | 0 (0) | 0.371 |
| SUVmean | 1.85 (1.56–2.08) | 1.62 (1.29–1.93) | 0.021 |
| Thyroid gland | |||
| Visual thyroiditis | 0 (0) | 1 (2.3) | 1.000 |
| Visual multinodular struma | 1 (4.0) | 5 (11.4) | 0.406 |
| SUVmean | 1.60 (1.33–1.99) | 1.54 (1.25–2.00) | 0.837 |
| Lungs | |||
| Visual inflammatory | 5 (19.2) | 6 (13.6) | 0.534 |
| Visual interstitial | 1 (3.8) | 4 (9.1) | 0.644 |
| Visual lung nodule | 8 (30.8) | 3 (6.8) | 0.015 |
| SUVmean (normal lung parenchyma) | 0.54 (0.47–0.67) | 0.56 (0.41–0.68) | 0.627 |
Data are presented as number (%) or median (interquartile range). Bold text highlights significant values. pSS; primary SS: SUVmax/SUVmean: maximum/mean standardized uptake value.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
